Humanized scFv Antibodies Targeting CCK-BR for Neuropathic Pain
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chronic pain resulting from traumatic nerve injuries, such as those caused by blunt force trauma, often transitions to neuropathic pain due to nerve overactivation and central sensitization, with existing treatments like opioids having limitations and side effects.
Innovation Solution
Development of humanized non-opioid small antibodies, specifically single-chain variable fragment (scFv) antibodies targeting the CCK-BR receptor, which are administered intranasally or subcutaneously to inhibit CCK-BR activity, reducing nerve activation and associated chronic pain, anxiety, and depression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If opioids are used to treat chronic pain from nerve injuries, then pain relief is achieved, but side effects and limitations occur
Solution Approach 1:
The patent introduces a non-opioid medicinal compound as an intermediary substance that acts on the CCK-BR receptor to provide pain relief without the harmful side effects of opioids. This mediator approach allows pain management through a different biochemical pathway, avoiding the harmful effects associated with opioid receptor activation while maintaining effective pain control.
2Duration of action of moving object
If traditional pain treatments are used, then acute pain is managed, but chronic pain from nerve injury persists due to central sensitization
Solution Approach 1:
The patent applies preliminary action by targeting and blocking the CCK-BR receptor before chronic pain fully develops. The medicinal compound pre-empts the development of central sensitization by inhibiting the receptor's activation during the transition from acute to chronic pain, thereby preventing the establishment of persistent pain pathways rather than merely managing symptoms after they have established.
3Object-affected harmful factors
If nerve injury treatments are administered, then pain is reduced, but anxiety and depression-like behaviors develop
Solution Approach 1:
The patent demonstrates multi-functionality by showing that the CCK-BR receptor antagonist has broad effects beyond pain control. The same medicinal compound that reduces neuropathic pain also prevents anxiety and depression-like behaviors, indicating that the receptor plays a universal role in multiple aspects of neural function and that a single treatment can address multiple comorbid conditions simultaneously.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The humanized scFv antibodies effectively alleviate chronic pain, prevent anxiety and depression, and restore neuronal firing to baseline, demonstrating significant pain relief and behavioral improvements in various nerve injury models.
Implementation Method 1
A panel of small murine single-chain variable fragment (scFv) antibodies recognizing a peptide of CCKBR (CCKB receptor is a cholecystokinin B receiver) were generated with cell-free ribosome display technology. The scFv antibodies feature binding activity similar to monoclonal antibodies but with stronger affinity and increased tissue penetrability due to their smaller size.
Implementation Method 2
The scFv antibodies feature binding activity similar to monoclonal antibodies but with stronger affinity and increased tissue penetrability due to their smaller size.
Data Source
AI summary
Antibodies or portions thereof specific for human CCKBR, a composition comprising the antibody or portion thereof, an isolated cell expressing the antibody or portion thereof, and a method to inhibit or treat pain by using the antibody or portion thereof, are provided.